Skip to main content
. 2022 Oct 14;2022:9494910. doi: 10.1155/2022/9494910

Figure 4.

Figure 4

miR-3613-5p targets PTEN. (a) qRT-PCR was used to assess the relative level of PTEN in MCF-7, MCF-7/DOX, MDA-MB-231, and MDA-MB-231/DOX cells. ∗∗p < 0.01. Data are mean ± S.D. of 3 independent experiments. (b) Western blotting was used to detect the protein expression of PTEN in MCF-7, MCF-7/DOX, MDA-MB-231, and MDA-MB-231/DOX cells. ∗∗p < 0.01. Data are mean ± S.D. of 3 independent experiments. (c) Website TargetScan predicted the binding site of PTEN to miR-3613-5p. (d) Dual luciferase reporter assay was performed to detect the luciferase activity in wild-type (WT) and mutant (MUT) of MCF-7/DOX and MDA-MB-231/DOX cells after transfection with NC mimics and miR-3613-5p mimics. ∗∗p < 0.01. Data are mean ± S.D. of 3 independent experiments. (e) qRT-PCR was used to assess the relative levels of miR-3613-5p and PTEN in MCF-7/DOX and MDA-MB-231/DOX cells. ∗∗p < 0.01. Data are mean ± S.D. of 3 independent experiments. (f) Western blotting was used to detect the protein expression of PTEN in MCF-7/DOX and MDA-MB-231/DOX cells after the treatments of NC inhibitor and miR-3613-5p inhibitor. ∗∗p < 0.01. Data are mean ± S.D. of 3 independent experiments.